Alnylam ( Alnylam)

Primary tabs

Alnylam's picture

Management

Contact Address

About Alnylam

Alnylam is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

Alnylam press release, blog etc

Thu, 12/11/2025 - 21:02 Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
Sun, 09/28/2025 - 12:04 New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
Wed, 09/10/2025 - 06:06 Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
Mon, 09/08/2025 - 19:28 Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
Thu, 06/19/2025 - 04:40 Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
Mon, 06/09/2025 - 14:36 Alnylam Receives European Commission Approval for AMVUTTRA (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Tue, 05/20/2025 - 15:58 AMVUTTRA (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
Mon, 05/12/2025 - 07:27 Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
Mon, 04/28/2025 - 17:39 Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Fri, 03/28/2025 - 17:35 FDA Approves Qfitlia (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
Wed, 03/05/2025 - 07:02 Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
Wed, 08/07/2024 - 13:27 Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
Wed, 12/21/2022 - 06:11 Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
Thu, 12/15/2022 - 04:55 Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
Wed, 12/07/2022 - 19:25 Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Thu, 12/01/2022 - 06:52 Alnylam Ranks #1 on Boston Globes Top Places to Work List for 2022
Thu, 10/27/2022 - 14:46 Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
Wed, 09/21/2022 - 04:08 Alnylam Announces New Management Appointments
more

InfoBox

HomePagewww.alnylam.com
Twittertwitter.com/Alnylam
YouTubewww.youtube.com/channel/UCUZReY0GSAJ1w-MULQb9_Rw
LinkedInwww.linkedin.com/company/alnylam-pharmaceuticals
Wikipediaen.wikipedia.org/wiki/Alnylam_Pharmaceuticals